Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression.

Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S.

Cell Mol Immunol. 2014 Sep;11(5):495-502. doi: 10.1038/cmi.2014.30. Epub 2014 May 12.

2.

Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis.

Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I.

Cancer Immunol Immunother. 2009 May;58(5):641-52. doi: 10.1007/s00262-008-0585-3. Epub 2008 Sep 13.

PMID:
18791713
3.

Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.

Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A.

J Immunol. 2005 Jul 15;175(2):720-9.

4.

Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.

Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G, Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M.

FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.

PMID:
23395909
5.

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A.

Cancer Res. 2002 Nov 1;62(21):6178-86.

6.

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.

Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V.

Neoplasia. 2004 Sep-Oct;6(5):558-68.

7.

Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.

Xu X, Rao G, Gaffud MJ, Ding HG, Maki G, Klingemann HG, Groh V, Spies T, Caillat-Zucman S, Gattuso P, Plate J, Prinz RA.

J Clin Endocrinol Metab. 2006 Jul;91(7):2704-12. Epub 2006 Apr 18.

PMID:
16621903
8.

Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.

Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, Wikström P.

PLoS One. 2014 Sep 30;9(9):e108925. doi: 10.1371/journal.pone.0108925. eCollection 2014.

9.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

10.

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.

He S, Yin T, Li D, Gao X, Wan Y, Ma X, Ye T, Guo F, Sun J, Lin Z, Wang Y.

J Transl Med. 2013 Aug 12;11:186. doi: 10.1186/1479-5876-11-186.

11.
12.

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T.

Science. 1999 Jul 30;285(5428):727-9.

13.

The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands.

Suzuki T, Terao S, Acharya B, Naoe M, Yamamoto S, Okamura H, Gotoh A.

Anticancer Res. 2010 Nov;30(11):4509-13.

PMID:
21115900
14.

Human tumor-derived exosomes down-modulate NKG2D expression.

Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z.

J Immunol. 2008 Jun 1;180(11):7249-58.

15.

Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

Song H, Kim J, Cosman D, Choi I.

Cell Immunol. 2006 Jan;239(1):22-30. Epub 2006 Apr 21.

PMID:
16630603
16.

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM.

J Immunol. 2003 Dec 15;171(12):6891-9.

17.

Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.

Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T, Fukunaga S, Futani H, Okamura H, Terada N.

Oncol Rep. 2010 Dec;24(6):1621-7.

PMID:
21042760
18.

Interleukin 10 decreases MICA expression on melanoma cell surface.

Serrano AE, Menares-Castillo E, Garrido-Tapia M, Ribeiro CH, Hernández CJ, Mendoza-Naranjo A, Gatica-Andrades M, Valenzuela-Diaz R, Zúñiga R, López MN, Salazar-Onfray F, Aguillón JC, Molina MC.

Immunol Cell Biol. 2011 Mar;89(3):447-57. doi: 10.1038/icb.2010.100. Epub 2010 Aug 17.

PMID:
20714339
19.

Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.

Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, Contreras-Paredes A, Dueñas-González A.

Int J Oncol. 2011 Dec;39(6):1491-9. doi: 10.3892/ijo.2011.1144. Epub 2011 Jul 26.

PMID:
21805029
20.

Activation of V gamma 9V delta 2 T cells by NKG2D.

Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T.

J Immunol. 2005 Aug 15;175(4):2144-51.

Supplemental Content

Support Center